Share of Clicks for top 10 US Pharma & Biotech Neuroscience brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| vraylar.com | 25.67 |
| caplyta.com | 17.03 |
| rexulti.com | 14.28 |
| vraylarhcp.com | 10.55 |
| nurtec.com | 5.49 |
| vyepti.com | 4.48 |
| rexultihcp.com | 3.42 |
| caplytahcp.com | 3.07 |
| wakixhcp.com | 1.23 |
| fanapt.com | 1.22 |
| others | 13.56 |
- vraylar.com - 25.67%
- caplyta.com - 17.03%
- rexulti.com - 14.28%
- vraylarhcp.com - 10.55%
- nurtec.com - 5.49%
- vyepti.com - 4.48%
- rexultihcp.com - 3.42%
- caplytahcp.com - 3.07%
- wakixhcp.com - 1.23%
- fanapt.com - 1.22%
- others - 13.56%
Copyright © Adthena. All rights reserved.
In the competitive landscape of Google PPC, Vraylar.com leads with 25.67% click share, followed by Caplyta.com at 17.03%. Rexulti.com captures 14.28%, while ‘others’ collectively hold 13.56%.
Share of Spend for the top 10 US Pharma & Biotech Neuroscience brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | vraylar.com | caplyta.com | rexulti.com | vraylarhcp.com | caplytahcp.com | rexultihcp.com | vyepti.com | nurtec.com | parkinson.org | wakix.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/04/01 | 31.12% | 18.45% | 7.11% | 17.75% | 1.39% | 2.26% | 5.48% | 5.13% | 0.7% | 1.62% |
| 2026/04/02 | 26.84% | 20.81% | 10.13% | 13.24% | 2.84% | 3.28% | 4.95% | 5.73% | 1.15% | 1.58% |
| 2026/04/03 | 30.93% | 22.42% | 3.26% | 18.95% | 1.25% | 0.89% | 3.59% | 4.35% | 0.93% | 1.82% |
| 2026/04/04 | 25.12% | 18.97% | 7.13% | 17.12% | 1.79% | 4.06% | 3.56% | 3.64% | 0.82% | 1.78% |
| 2026/04/05 | 28.83% | 19.67% | 8.21% | 15.41% | 2.08% | 3.34% | 3.19% | 3.55% | 1.08% | 2.01% |
| 2026/04/06 | 25.16% | 18.17% | 14.04% | 15.85% | 1.55% | 5.35% | 3.67% | 5.34% | 0.1% | 1.64% |
| 2026/04/07 | 26.47% | 20% | 6.32% | 17.75% | 4.85% | 3.54% | 2.96% | 4.62% | 0.76% | 1.44% |
| 2026/04/08 | 30.31% | 19.12% | 10.2% | 17.6% | 2.39% | 4.81% | 2.26% | 4.57% | 0.58% | 1.28% |
| 2026/04/09 | 31.46% | 19.91% | 7.1% | 16.72% | 5.44% | 2.56% | 3.66% | 4.15% | 0.6% | 1.25% |
| 2026/04/10 | 30.36% | 16.9% | 4.96% | 21.6% | 6.12% | 2.28% | 3.09% | 3.35% | 0.74% | 0.95% |
| 2026/04/11 | 33.34% | 20.5% | 7.43% | 21.61% | 1.44% | 2.56% | 2.74% | 2.09% | 0.17% | 0.9% |
| 2026/04/12 | 28.26% | 20.16% | 6.36% | 19.02% | 4.66% | 2.32% | 2.22% | 3.61% | 0.81% | 1.24% |
| 2026/04/13 | 30.11% | 19.31% | 13.13% | 15.64% | 0.64% | 4.61% | 2.54% | 2.84% | 1.06% | 1.37% |
| 2026/04/14 | 31.06% | 23.45% | 4.56% | 16.92% | 0.66% | 1.64% | 3.33% | 3.33% | 2.23% | 1.04% |
| 2026/04/15 | 27.66% | 18.12% | 12.23% | 16.43% | 4.99% | 4.16% | 3.18% | 2.66% | 1.22% | 0.83% |
| 2026/04/16 | 35.4% | 14.64% | 2.15% | 18.84% | 8.48% | 1.92% | 2.84% | 3.02% | 2.79% | 0.6% |
| 2026/04/17 | 32.53% | 20.32% | 12.12% | 12.34% | 3.51% | 4% | 2.38% | 3.67% | 1.79% | 1.33% |
| 2026/04/18 | 29.13% | 22% | 5.47% | 12.09% | 5.73% | 1.53% | 3.77% | 2.65% | 1.42% | 0.81% |
| 2026/04/19 | 27.33% | 19.43% | 13.08% | 12.78% | 0.24% | 4.93% | 3.51% | 3.11% | 3.97% | 0.65% |
| 2026/04/20 | 25.16% | 20.9% | 11.09% | 12.39% | 5.57% | 4.31% | 3.28% | 4.2% | 1.2% | 1.17% |
| 2026/04/21 | 29.06% | 17.28% | 11.43% | 11.78% | 5.64% | 4.57% | 3.78% | 3.13% | 0.7% | 0.87% |
| 2026/04/22 | 28.13% | 17.62% | 12.68% | 14.88% | 3.81% | 4.54% | 3.02% | 3.06% | 0.58% | 0.73% |
| 2026/04/23 | 27.15% | 17.9% | 8.48% | 17.21% | 3.8% | 3.5% | 3.64% | 3.25% | 1.11% | 1.27% |
| 2026/04/24 | 22.69% | 19.97% | 13.89% | 12.76% | 1.59% | 5.4% | 3.56% | 3.46% | 2.07% | 0.62% |
| 2026/04/25 | 27.59% | 16.01% | 11.67% | 16.29% | 3.81% | 3.99% | 3.22% | 3.3% | 1.72% | 0.72% |
| 2026/04/26 | 23.62% | 17.86% | 11.62% | 10.45% | 4.38% | 4.56% | 5.11% | 2.36% | 2.25% | 0.92% |
| 2026/04/27 | 26.4% | 19.98% | 9.59% | 14.82% | 5.41% | 3.67% | 3.1% | 4.22% | 0.62% | 0.62% |
| 2026/04/28 | 24.28% | 16.64% | 13.83% | 12.2% | 5.56% | 5.1% | 3.26% | 2.79% | 2.53% | 1.19% |
| 2026/04/29 | 24.95% | 14.5% | 14.33% | 15.46% | 6.66% | 5.63% | 3.73% | 3.33% | 0.87% | 0.61% |
| 2026/04/30 | 23.48% | 19.84% | 13.9% | 10.2% | 6.87% | 4.66% | 3.48% | 3.43% | 1.56% | 0.69% |
- vraylar.com
- caplyta.com
- rexulti.com
- vraylarhcp.com
- caplytahcp.com
- rexultihcp.com
- vyepti.com
- nurtec.com
- parkinson.org
- wakix.com
Copyright © Adthena. All rights reserved.
April saw vraylar.com lead with fluctuating spend, peaking mid-month. Caplyta.com maintained a steady presence, while rexulti.com showed sporadic spikes. Vraylarhcp.com and caplytahcp.com had varied trends, ending with moderate shares.
Competitor Count for US Pharma & Biotech Neuroscience
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/04/01 | 70 |
| 2026/04/02 | 70 |
| 2026/04/03 | 78 |
| 2026/04/04 | 83 |
| 2026/04/05 | 79 |
| 2026/04/06 | 80 |
| 2026/04/07 | 78 |
| 2026/04/08 | 76 |
| 2026/04/09 | 73 |
| 2026/04/10 | 77 |
| 2026/04/11 | 69 |
| 2026/04/12 | 69 |
| 2026/04/13 | 72 |
| 2026/04/14 | 71 |
| 2026/04/15 | 70 |
| 2026/04/16 | 68 |
| 2026/04/17 | 63 |
| 2026/04/18 | 72 |
| 2026/04/19 | 76 |
| 2026/04/20 | 75 |
| 2026/04/21 | 82 |
| 2026/04/22 | 79 |
| 2026/04/23 | 83 |
| 2026/04/24 | 77 |
| 2026/04/25 | 84 |
| 2026/04/26 | 82 |
| 2026/04/27 | 81 |
| 2026/04/28 | 77 |
| 2026/04/29 | 79 |
| 2026/04/30 | 79 |
Copyright © Adthena. All rights reserved.
April began with 70 advertisers, peaking at 84 mid-month. Fluctuations followed, ending at 79.
